{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:26:33Z","timestamp":1786987593055,"version":"build-2736575974"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,26]],"date-time":"2025-01-26T00:00:00Z","timestamp":1737849600000},"content-version":"vor","delay-in-days":391,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment and Research Communications"],"published-print":{"date-parts":[[2024]]},"DOI":"10.1016\/j.ctarc.2025.100874","type":"journal-article","created":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T19:37:32Z","timestamp":1738006652000},"page":"100874","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["PARP inhibitors as therapy for small cell lung carcinoma: A systematic review and meta-analysis of clinical trials"],"prefix":"10.1016","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9532-1442","authenticated-orcid":false,"given":"Samuel","family":"Pratama","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lowilius","family":"Wiyono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martien Silviandy","family":"Setiawan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigitta Cindy","family":"Lauren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.ctarc.2025.100874_bib0001","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/nrc.2017.87","article-title":"Small-cell lung cancer: what we know, what we need to know and the path forward","volume":"17","author":"Gazdar","year":"2017","journal-title":"Nat. Rev. Cancer"},{"issue":"34","key":"10.1016\/j.ctarc.2025.100874_bib0002","doi-asserted-by":"crossref","first-page":"4106","DOI":"10.1200\/JCO.2015.63.7918","article-title":"Treatment of small-cell lung cancer: american society of clinical oncology endorsement of the american college of chest physicians guideline","volume":"33","author":"Rudin","year":"2015","journal-title":"J. Clin. Oncol. Off J. Am. Soc. Clin. Oncol"},{"key":"10.1016\/j.ctarc.2025.100874_bib0003","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.lungcan.2017.10.006","article-title":"Targeting DNA damage in SCLC","volume":"114","author":"Foy","year":"2017","journal-title":"Lung Cancer Amst. Neth"},{"issue":"2","key":"10.1016\/j.ctarc.2025.100874_bib0004","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1097\/JTO.0b013e318160c0cb","article-title":"Outcomes of second-line chemotherapy in patients with relapsed extensive small cell lung cancer","volume":"3","author":"Froeschl","year":"2008","journal-title":"J. Thorac. Oncol."},{"issue":"12","key":"10.1016\/j.ctarc.2025.100874_bib0005","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1038\/nrc3399","article-title":"DNA repair dysregulation from cancer driver to therapeutic target","volume":"12","author":"Curtin","year":"2012","journal-title":"Nat. Rev. Cancer"},{"issue":"8","key":"10.1016\/j.ctarc.2025.100874_bib0006","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1002\/bies.20085","article-title":"The PARP superfamily","volume":"26","author":"Am\u00e9","year":"2004","journal-title":"BioEssays News Rev. Mol. Cell Dev. Biol"},{"issue":"15","key":"10.1016\/j.ctarc.2025.100874_bib0007","doi-asserted-by":"crossref","first-page":"8412","DOI":"10.3390\/ijms23158412","article-title":"PARP inhibitors: clinical limitations and recent attempts to overcome them","volume":"23","author":"Kim","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"9","key":"10.1016\/j.ctarc.2025.100874_bib0008","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1158\/2159-8290.CD-12-0112","article-title":"Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1","volume":"2","author":"Byers","year":"2012","journal-title":"Cancer Discov."},{"issue":"1","key":"10.1016\/j.ctarc.2025.100874_bib0009","doi-asserted-by":"crossref","first-page":"94","DOI":"10.15252\/embr.201540964","article-title":"SLFN11 inhibits checkpoint maintenance and homologous recombination repair","volume":"17","author":"Mu","year":"2016","journal-title":"EMBo Rep."},{"issue":"2","key":"10.1016\/j.ctarc.2025.100874_bib0010","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.ccell.2017.01.006","article-title":"Chemosensitive Relapse in Small Cell Lung Cancer Proceeds through an EZH2-SLFN11 Axis","volume":"31","author":"Gardner","year":"2017","journal-title":"Cancer Cell"},{"issue":"2","key":"10.1016\/j.ctarc.2025.100874_bib0011","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1158\/1078-0432.CCR-16-1040","article-title":"PARP inhibitor activity correlates with SLFN11 expression and demonstrates synergy with temozolomide in small cell lung cancer","volume":"23","author":"Lok","year":"2017","journal-title":"Clin. Cancer Res. Off J. Am. Assoc. Cancer Res"},{"issue":"1","key":"10.1016\/j.ctarc.2025.100874_bib0012","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/jrsm.1230","article-title":"Basics of meta-analysis: I2 is not an absolute measure of heterogeneity","volume":"8","author":"Borenstein","year":"2017","journal-title":"Res. Synth. Methods"},{"issue":"23","key":"10.1016\/j.ctarc.2025.100874_bib0013","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1200\/JCO.2018.77.7672","article-title":"Randomized, double-blind, phase II study of temozolomide in combination with either veliparib or placebo in patients with relapsed-sensitive or refractory small-cell lung cancer","volume":"36","author":"Pietanza","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.ctarc.2025.100874_bib0014","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1200\/JCO.18.00264","article-title":"Randomized phase II trial of cisplatin and etoposide in combination with veliparib or placebo for extensive-stage small-cell lung cancer: ECOG-ACRIN 2511 study","volume":"37","author":"Owonikoko","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.ctarc.2025.100874_bib0015","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/j.jtho.2021.04.001","article-title":"Efficacy and safety of niraparib as maintenance treatment in patients with extensive-stage SCLC after first-line chemotherapy: a randomized, double-blind, phase 3 study","volume":"16","author":"Ai","year":"2021","journal-title":"J. Thorac. Oncol."},{"issue":"14","key":"10.1016\/j.ctarc.2025.100874_bib0016","doi-asserted-by":"crossref","first-page":"3884","DOI":"10.1158\/1078-0432.CCR-20-4259","article-title":"Veliparib in combination with carboplatin and etoposide in patients with treatment-na\u00efve extensive-stage small cell lung cancer: a phase 2 randomized study","volume":"27","author":"Byers","year":"2021","journal-title":"Clin. Cancer Res. Off J. Am. Assoc. Cancer Res"},{"key":"10.1016\/j.ctarc.2025.100874_bib0017","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.lungcan.2022.07.007","article-title":"Olaparib as maintenance treatment in patients with chemosensitive small cell lung cancer (STOMP): A randomised, double-blind, placebo-controlled phase II trial","volume":"171","author":"Woll","year":"2022","journal-title":"Lung Cancer Amst. Neth"},{"issue":"16_suppl","key":"10.1016\/j.ctarc.2025.100874_bib0018","doi-asserted-by":"crossref","first-page":"5580","DOI":"10.1200\/JCO.2023.41.16_suppl.5580","article-title":"Exploring the significance of PARP inhibitor therapy after first-line chemotherapy in patients with homologous recombination proficient ovarian cancer: An extracted individual patient data and trial-level meta-analysis","volume":"41","author":"Cunha","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.ctarc.2025.100874_bib0019","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s13048-024-01362-y","article-title":"PARP inhibitor era in ovarian cancer treatment: a systematic review and meta-analysis of randomized controlled trials","volume":"17","author":"Barad\u00e1cs","year":"2024","journal-title":"J. Ovarian. Res."},{"issue":"5","key":"10.1016\/j.ctarc.2025.100874_bib0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100558","article-title":"Maintenance therapy with a poly(ADP-ribose) polymerase inhibitor in patients with newly diagnosed advanced epithelial ovarian cancer: individual patient data and trial-level meta-analysis\u2606","volume":"7","author":"Gulia","year":"2022","journal-title":"ESMo Open."},{"issue":"1","key":"10.1016\/j.ctarc.2025.100874_bib0021","doi-asserted-by":"crossref","DOI":"10.1080\/01443615.2023.2171282","article-title":"Efficacy and safety of PARP inhibitors for maintenance treatment of ovarian cancer, regardless of BRCA or HRD status: a comprehensive updated meta-analysis","volume":"43","author":"Li","year":"2023","journal-title":"J. Obstet. Gynaecol. J. Inst. Obstet. Gynaecol"},{"issue":"11","key":"10.1016\/j.ctarc.2025.100874_bib0022","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0294647","article-title":"Impact of PARP inhibitor maintenance therapy in newly diagnosed advanced epithelial ovarian cancer: A meta-analysis","volume":"18","author":"Lee","year":"2023","journal-title":"PLoS. One"},{"issue":"3","key":"10.1016\/j.ctarc.2025.100874_bib0023","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1080\/17512433.2023.2188193","article-title":"Efficacy and safety of PARP inhibitors in the treatment of BRCA-mutated breast cancer: an updated systematic review and meta-analysis of randomized controlled trials","volume":"16","author":"Sun","year":"2023","journal-title":"Expert. Rev. Clin. Pharmacol."},{"issue":"10","key":"10.1016\/j.ctarc.2025.100874_bib0024","doi-asserted-by":"crossref","first-page":"9262","DOI":"10.3390\/curroncol30100669","article-title":"A meta-analysis of randomized clinical trials assessing the efficacy of PARP inhibitors in metastatic castration-resistant prostate cancer","volume":"30","author":"Alameddine","year":"2023","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.ctarc.2025.100874_bib0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2023.102623","article-title":"Efficacy and safety of PARP inhibitors in metastatic castration-resistant prostate cancer: A systematic review and meta-analysis of clinical trials","volume":"120","author":"Iannantuono","year":"2023","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.ctarc.2025.100874_bib0026","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.777663","article-title":"Evaluation of the efficacy of PARP inhibitors in metastatic castration-resistant prostate cancer: a systematic review and meta-analysis","volume":"12","author":"Wu","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ctarc.2025.100874_bib0027","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1056\/NEJMoa1706450","article-title":"Olaparib for metastatic breast cancer in patients with a germline BRCA mutation","volume":"377","author":"Robson","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"26","key":"10.1016\/j.ctarc.2025.100874_bib0028","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","article-title":"Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer","volume":"379","author":"Moore","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.ctarc.2025.100874_bib0029","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1200\/JCO.22.01549","article-title":"Overall survival with maintenance olaparib at a 7-year follow-up in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation: the SOLO1\/GOG 3004 trial","volume":"41","author":"DiSilvestro","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.ctarc.2025.100874_bib0030","first-page":"1447","article-title":"Durvalumab in combination with olaparib in patients with relapsed SCLC: results from a phase II study","volume":"14","author":"Thomas","year":"2019","journal-title":"J. Thorac. Oncol. Off. Publ. Int. Assoc. Study Lung. Cancer"},{"key":"10.1016\/j.ctarc.2025.100874_bib0031","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2023.107216","article-title":"Olaparib and durvalumab in patients with relapsed small cell lung cancer (MEDIOLA): An open-label, multicenter, phase 1\/2, basket study","volume":"180","author":"Krebs","year":"2023","journal-title":"Lung Cancer"},{"issue":"16_suppl","key":"10.1016\/j.ctarc.2025.100874_bib0032","doi-asserted-by":"crossref","first-page":"8504","DOI":"10.1200\/JCO.2023.41.16_suppl.8504","article-title":"SWOG S1929: Phase II randomized study of maintenance atezolizumab (A) versus atezolizumab + talazoparib (AT) in patients with SLFN11 positive extensive stage small cell lung cancer (ES-SCLC)","volume":"41","author":"Abdel Karim","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2025.100874_bib0033","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2020.103145","article-title":"Efficacy and safety of PARP inhibitors in the treatment of advanced ovarian cancer: An updated systematic review and meta-analysis of randomized controlled trials","volume":"157","author":"Hao","year":"2021","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"4","key":"10.1016\/j.ctarc.2025.100874_bib0034","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1093\/annonc\/mdz012","article-title":"OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer","volume":"30","author":"Robson","year":"2019","journal-title":"Ann. Oncol."},{"issue":"7563","key":"10.1016\/j.ctarc.2025.100874_bib0035","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nature14664","article-title":"Comprehensive genomic profiles of small cell lung cancer","volume":"524","author":"George","year":"2015","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.ctarc.2025.100874_bib0036","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1038\/s41416-020-01202-y","article-title":"The role of Schlafen 11 (SLFN11) as a predictive biomarker for targeting the DNA damage response","volume":"124","author":"Coleman","year":"2021","journal-title":"Br. J. Cancer"},{"issue":"531","key":"10.1016\/j.ctarc.2025.100874_bib0037","doi-asserted-by":"crossref","first-page":"eaax2625","DOI":"10.1126\/scitranslmed.aax2625","article-title":"BRCAness, SLFN11, and RB1 loss predict response to topoisomerase I inhibitors in triple-negative breast cancers","volume":"12","author":"Coussy","year":"2020","journal-title":"Sci. Transl. Med."},{"issue":"12","key":"10.1016\/j.ctarc.2025.100874_bib0038","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1038\/s41416-021-01560-1","article-title":"Retrospective analysis of Schlafen11 (SLFN11) to predict the outcomes to therapies affecting the DNA damage response","volume":"125","author":"Willis","year":"2021","journal-title":"Br. J. Cancer"},{"issue":"12","key":"10.1016\/j.ctarc.2025.100874_bib0039","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.3390\/ph15121475","article-title":"Targeting the DNA damage response machinery for lung cancer treatment","volume":"15","author":"Venugopala","year":"2022","journal-title":"Pharmaceuticals"},{"issue":"3","key":"10.1016\/j.ctarc.2025.100874_bib0040","doi-asserted-by":"crossref","first-page":"415","DOI":"10.3233\/CBM-160580","article-title":"Prognostic significance of serum LDH in small cell lung cancer: A systematic review with meta-analysis","volume":"16","author":"Zhang","year":"2016","journal-title":"Cancer Biomark. Sect. Dis. Markers"},{"issue":"17","key":"10.1016\/j.ctarc.2025.100874_bib0041","doi-asserted-by":"crossref","first-page":"28575","DOI":"10.18632\/oncotarget.15338","article-title":"Dynamic variations in epithelial-to-mesenchymal transition (EMT), ATM, and SLFN11 govern response to PARP inhibitors and cisplatin in small cell lung cancer","volume":"8","author":"Stewart","year":"2017","journal-title":"Oncotarget."},{"issue":"3","key":"10.1016\/j.ctarc.2025.100874_bib0042","doi-asserted-by":"crossref","first-page":"e468","DOI":"10.1016\/j.ijrobp.2021.07.1308","article-title":"Phase 3 study of pembrolizumab with concurrent chemoradiation therapy followed by pembrolizumab with or without olaparib vs. concurrent chemoradiation therapy in patients with newly diagnosed limited-stage small-cell lung cancer: KEYLYNK-013","volume":"111","author":"Rimner","year":"2021","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"1","key":"10.1016\/j.ctarc.2025.100874_bib0043","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s13014-024-02437-2","article-title":"Pamiparib as consolidation treatment after concurrent chemoradiotherapy of limited-stage small cell lung cancer: a single-arm, open-label phase 2 trial","volume":"19","author":"Mao","year":"2024","journal-title":"Radiat. Oncol."}],"container-title":["Cancer Treatment and Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294225000127?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294225000127?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,8]],"date-time":"2025-02-08T07:36:33Z","timestamp":1739000193000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468294225000127"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"references-count":43,"alternative-id":["S2468294225000127"],"URL":"https:\/\/doi.org\/10.1016\/j.ctarc.2025.100874","relation":{},"ISSN":["2468-2942"],"issn-type":[{"value":"2468-2942","type":"print"}],"subject":[],"published":{"date-parts":[[2024]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"PARP inhibitors as therapy for small cell lung carcinoma: A systematic review and meta-analysis of clinical trials","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment and Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctarc.2025.100874","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100874"}}